BioStock Feed

2026-09-01 09:46:00 Pila Pharma takes the next step toward higher doses in the PP-CT04 study

2026-09-01 09:46:00 Pila Pharma takes the next step toward higher doses in PP-CT04 study

2026-08-28 10:52:00 Curasight: Letting the data guide uTREAT development

2026-08-25 13:27:00 BioStock publicerar Consensus Analysis för Zealand Pharma

2026-08-21 11:05:00 BioStock publicerar Consensus Analysis för Genmab

2026-08-19 13:38:00 Regulatory green light takes Pila Pharma’s obesity candidate into mid-stage testing

2026-08-19 13:38:00 Regulatoriskt klartecken tar Pila Pharmas obesitaskandidat till mellanfas

2026-08-18 15:42:00 BioStock publicerar Consensus Analysis för Novo Nordisk

2026-08-18 09:15:00 Saniona on the equity and milestone upside in the AstronauTx deal

2026-08-13 12:26:00 BioStock publicerar Consensus Analysis för Swedish Orphan Biovitrum

2026-08-11 10:14:00 BioStock publicerar Consensus Analysis för Getinge

2026-08-06 14:34:00 BioStock publicerar Consensus Analysis för AstraZeneca

2026-07-20 11:58:00 SynAct comments on the SEK 100 million facility

2026-07-08 08:30:00 Between China, Wall Street and Nasdaq Stockholm | Market Signal #4

2026-07-08 08:30:00 Mellan Kina, Wall Street och Stockholmsbörsen | Market Signal #4

2026-07-07 07:09:00 BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B

2026-07-07 07:09:00 BioVal™-analys av Alzinovas ALZ-101 – rNPV om 7,1 miljarder SEK

2026-07-03 09:29:00 BioStock publishes the Q2 2026 edition of State of Nordic Biopharma

2026-07-03 09:29:00 BioStock publicerar Q2 2026-utgåvan av State of Nordic Biopharma

2026-07-02 07:27:00 BioStock publish BioVal™ analysis of Elicera Therapeutics' ELC-301 programme

2026-07-02 07:27:00 BioStock publicerar BioVal™-analys av Elicera Therapeutics ELC-301-projekt

2026-07-02 07:26:00 BioStock launches the rNPV platform BioVal™ and publishes its first analysis

2026-07-02 07:26:00 BioStock lanserar rNPV-plattformen BioVal™ och publicerar den första analysen

2026-06-11 09:10:00 Three shots on goal: Saniona prepares to enter the clinic

2026-06-10 09:15:00 Curasight reports promising early preliminary uTREAT phase I data

2026-06-03 09:12:00 Erik Selin's biotech venture and Vicore's Nasdaq plans | Market Signal #3

2026-06-03 09:12:00 Erik Selins biotech-satsning och Vicores Nasdaq-planer | Market Signal #3

2026-05-29 10:19:00 Curasight advances uTREAT through first-in-human development as key clinical data approaches

2026-05-20 12:01:00 Partner feedback reshapes ExpreS2ion's ES2B-C001 programme as responses hit 9 of 9

2026-05-19 11:06:00 BioStock launches Consensus Analysis – a new analytical format for Nordic life science

2026-05-19 11:06:00 BioStock lanserar Consensus Analysis – ett nytt analytiskt format för nordisk life science

2026-05-08 13:10:00 Curasight nears topline results in brain and prostate cancer

2026-05-08 10:10:00 Spago Nanomedical reaches primary endpoint in Tumorad-01

2026-05-06 11:29:00 SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

2026-04-28 12:15:00 Pila Pharma on the preclinical results and the way forward

2026-04-28 12:15:00 Pila Pharma om de prekliniska resultaten och vägen framåt

2026-04-27 09:07:00 What good data looks like: SynAct Pharma ahead of its ADVANCE readout

2026-04-27 07:07:00 Zelluna entering the clinic with promising TCR-NK therapy

2026-04-27 07:07:00 Zelluna går in i klinik med lovande TCR-NK-terapi

2026-04-22 13:45:00 BioStock launches new TV format: Market Signal

2026-04-22 13:45:00 BioStock lanserar nytt TV-format: Market Signal

2026-04-20 08:42:00 ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million

2026-04-20 08:42:00 ExpreS2ion Biotech avancerar bröstcancerprojekt med företrädesemission om 53 Mkr

2026-04-17 09:58:00 Correction: Pila Pharma’s unanticipated obesity results plausibly explained by low drug exposure, analyses confirms

2026-04-17 09:58:00 Rättelse: Analys bekräftar att Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

2026-04-17 08:34:00 Pila Pharmas preclinical results plausibly explained by low drug exposure

2026-04-17 08:34:00 Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

2026-04-07 14:24:00 Biosergen halts BSG005 development

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode